“Fountain is an example of a biotech company emerging as a direct result of basic research, in this case the biology of aging,” said Dr Rando, founder and chairman of Fountain. “The company’s screening and discovery platform is built upon foundational research showing that the age of a cell can be modulated by factors in the cell’s environment. By identifying compounds that work through these pathways, we seek to restore youthful resilience to cells and tissues, leading to therapies that treat or even prevent chronic diseases of aging.”

When you’re heading up a fledgling biotech out to make a name for yourself in the middle of a wild industry boom, there’s one sure way to differentiate yourself that’s bound to attract universal nods.

While anti-depressants and therapy have helped, Evanston-based biotech company Aptinyx have a pill in the pipeline that they hope will prevent the trauma that triggers PTSD.

Meet the second group of 14 executives being honored in 2021.

Orchestra BioMed presentedlong-term clinical results and ISH subgroup data from the MODERATO II trial of BackBeat Cardiac Neuromodulation Therapy in patients with hypertension and an indication for a pacemaker. The results demonstrated a mean reduction of 17.5 mmHg in office systolic blood pressure in all BackBeat CNT treated patients who completed 24-month follow-up.

In late 2017, Discovery Labs was at the brink of falling apart. The company’s investors pulled out after Aerosurf, its sole remaining asset being developed as a treatment for premature infants with respiratory distress syndrome, failed to meet its endpoints in a Phase IIb study.

One of the greatest recent innovations in cancer treatment, CAR T therapies have sent some patients into long-lasting remission, with speedier recoveries, due to the lack of aggressive chemotherapy involved. They are the darling of numerous biopharma companies, including Sorrento Therapeutics, Kite Pharma (Gilead), and Allogene Therapeutics.

Pharmacokinetics data on vurolenatide, a long-acting glucagon-like peptide-1 (GLP-1) being developed for short-bowel syndrome (SBS), suggest that the drug could be given twice monthly or less, an improvement over existing GLP-2 drugs, which must be given at least weekly.